Home 9 Heart Failure 9 Ep.3 – Potential Treatment Options: A Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction – Prof. Javed Butler

Ep.3 – Potential Treatment Options: A Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction – Prof. Javed Butler

November 7, 2022

Episode 3 – Potential Treatment Options: A Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction – Prof. Javed Butler

We are joined by Professor Javed Butler, Chair of the Department of Medicine at University of Mississippi Medical Center in Jackson, Mississippi, United States. His main area of research is heart failure, a topic on which he’s authored more than 650 peer-reviewed publications.

In the last episode, we discussed some promising results in the EMPEROR-Preserved trials where empagliflozin was shown to benefit patients with preserved ejection fraction. In this podcast, we will discuss the benefits of empagliflozin in heart failure patients with reduced ejection fraction, with a particular emphasis on cardiovascular and renal outcomes.

Test your knowledge Ep.3

Thank you for watching. Please click one answer from the drop down menu below. Good luck!

1) SGLT-2 inhibitors are good antiglycaemic agents. However, this is not believed to be the mechanism by which empagliflozin reduces the risk of hospitalisation or death from heart failure. Which of the following statements is not correct, lending evidence to suggest the mechanism of action in empagliflozin in improving outcomes in heart failure patients is independent of blood glucose control?

2) At which stage were the earliest significant differences between the placebo and empagliflozin arms observed in the EMPEROR-Reduced Trial?

Reference link:

https://www.nejm.org/doi/full/10.1056/NEJMoa2022190

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”.

“Not intended for US & UK based healthcare professionals”.

Available now to stream on your favourite platform: